How are energy investors positioned?
SANTA MONICA - GoodRx (NASDAQ:GDRX), a healthcare platform maintaining impressive gross profit margins of 93.7% according to InvestingPro data, announced Monday that all strengths of Ozempic and Wegovy pens are now available to eligible self-paying patients for $499 per month through its platform, following a collaboration with Novo Nordisk.
This marks the first time Ozempic has been offered at this self-pay price point, potentially expanding access for patients lacking adequate insurance coverage for these GLP-1 medications.
According to the company, nearly 17 million people visited GoodRx seeking savings and information on GLP-1 medications in the past year, representing a 22% increase from the previous year.
"Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them," said Wendy Barnes, President and Chief Executive Officer of GoodRx, in a press release statement.
The company noted that insurance coverage remains challenging for many patients seeking these medications, particularly for weight loss treatments. GoodRx research indicates 19 million people lack coverage for GLP-1s prescribed for weight loss.
Dave Moore, Executive Vice President of US Operations at Novo Nordisk Inc., stated this initiative enables the company to provide their "authentic GLP-1 medicines" to GoodRx patients while supporting the launch of the new Ozempic self-pay offer for type 2 diabetes patients.
The medications are available at this price point at over 70,000 retail pharmacies nationwide, according to the announcement.
GoodRx operates as a platform for medication savings in the U.S., connecting consumers, healthcare professionals, payers, PBMs, pharmaceutical manufacturers, and retail pharmacies to facilitate prescription savings. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with analysts predicting continued profit growth this year. For deeper insights into GoodRx’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, GoodRx Holdings Inc. reported its second-quarter earnings for 2025, which fell short of market expectations. The company announced earnings per share of $0.09, slightly below the forecast of $0.10, and revenue of $203.1 million, missing the anticipated $205.87 million. Following the earnings release, several analysts adjusted their outlook on GoodRx. UBS lowered its price target to $4.25 from $5.25, maintaining a Neutral rating, citing the company’s downgraded guidance for 2025 due to Rite Aid’s bankruptcy and restructuring at a pharmacy benefit manager partner. Raymond James downgraded the stock from Strong Buy to Outperform and reduced its price target to $5.00 from $9.00. Morgan Stanley also lowered its price target to $5.00 from $6.00, noting the revenue and EBITDA results were slightly below consensus estimates. Additionally, Goldman Sachs reduced its price target to $3.75 from $5.00, highlighting challenges in the healthcare environment, including a major retail pharmacy bankruptcy. These developments reflect the ongoing adjustments in analyst expectations following GoodRx’s recent earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.